Hepatitis B Vaccination in HIV-infected Persons
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130302074142im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
In this study we compare the efficacy of two different HBV-vaccination schedules in HIV-infected persons concerning immune response and compliance. Short schedule: t=0,1,3 weeks and standard schedule: t=0,1,6 months.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Hepatitis B |
Biological: HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
Official Title: | Randomised Open Label Clinical Trial of the Immune Response to Hepatitis B Vaccination in HIV-infected Persons. |
- Measurement of anti-Hbs titer after completing hepatitis B vaccination.
- To compare response and compliance between two vaccination schedules: short and standard
Estimated Enrollment: | 800 |
Study Start Date: | April 2004 |
Study Completion Date: | February 2010 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
It is known that HIV-infected persons are more prone to develop chronic hepatitis B infection when they get infected with this virus. After developing chronic hepatitis B these patients are more likely to get livercirrosis and hepatocellular carcinoma (Bodsworth et al.).
Hepatitis B vaccination is available and the vaccine is about 95% protective in preventing immunocompetent persons from developing chronic hepatitis B infection (Lemon). The response on this vaccin is less effective in HIV-infected persons (Carne et al.). Furthermore there is a compliance problem in the standard scheme.
In this study we compare the efficacy of two different HBV vaccination schedules in HIV-infected persons concerning immune response and compliance. A short schedule: t=0,1,3 weeks, in which there are good results concerning immune response and compliance in immunocompetent persons (Saltog et al.) and the standard schedule: t=0,1,6 months. Patients not immune at week 28 will be offered boostervaccination. This consists of double doses at t=0,1,2 months.
800 persons are needed to show non-inferiority with lower margin of 10% of the short schedule in comparison with the control group. Powercalculation is 80%. Randomization is stratified according to CD4 count(CD4 <200, 200-500, >500).
The hypothesis of the study is a better compliance and a comparable immune response in the short schedule, through which persons will be protected against hepatitis B in an early stage.
![](https://webarchive.library.unt.edu/web/20130302074142im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV positive
- Negative for HBsAg and anti-HBc
- 18 years or older
Exclusion Criteria:
- previous Hepatitis B vaccination
- current opportunistic infection
![](https://webarchive.library.unt.edu/web/20130302074142im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Netherlands | |
Erasmus Medical Center | |
Rotterdam, Netherlands, 3000 CA |
Principal Investigator: | Theodora EM de Vries-Sluijs, MD | Erasmus Medical Center |
![](https://webarchive.library.unt.edu/web/20130302074142im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Publications:
Responsible Party: | Theodora EMS de Vries-Sluijs, ErasmusMC |
ClinicalTrials.gov Identifier: | NCT00230061 History of Changes |
Other Study ID Numbers: | SNO-T-07-102 |
Study First Received: | September 28, 2005 |
Last Updated: | June 1, 2010 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Erasmus Medical Center:
HIV |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Hepatitis Hepatitis A Hepatitis B Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections Hepadnaviridae Infections DNA Virus Infections |
ClinicalTrials.gov processed this record on February 28, 2013